Clinical trials
Enrolling by invitation trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 12 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Enrolling by invitation | 27 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tomsk National Research Medical Center of the Russian Academy of Sciences | 4 |
| I.M. Sechenov First Moscow State Medical University | 2 |
| Pirogov Russian National Research Medical University | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| Artgen Biotech | 1 |
| AstraZeneca | 1 |
| Bakulev Scientific Center of Cardiovascular Surgery | 1 |
| Blokhin's Russian Cancer Research Center | 1 |
| Central State Medical Academy | 1 |
| Grifols Therapeutics LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 3 |
| Asthma | 2 |
| Atrial Fibrillation | 2 |
| Cardiomyopathy, Hypertrophic | 2 |
| Cardiovascular Diseases | 2 |
| Diabetes Mellitus | 2 |
| Hypertension | 2 |
| Ischemic Stroke | 2 |
| Neoplasms | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
Trials
Showing 76 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.